/PRNewswire/ VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced it has been awarded a further $1.5.
VolitionRx (NYSE-A:VNRX) Limited revealed that it has been awarded a further $1.5 million in non-dilutive funding from Namur Invest Capital Risk in Belgium..